Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin + irinotecan
- Development stage
- Unknown
- Lead developer
- Hospital de Amor
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Metformin + irinotecan is an investigational drug combination being evaluated for the treatment of refractory metastatic or recurrent colorectal cancer. This specific therapeutic approach was the subject of a Phase II single-arm clinical trial (MetIri) conducted at Barretos Cancer Hospital in Brazil. Metformin, a biguanide small molecule traditionally used for type 2 diabetes, is being repurposed for its ability to activate AMP-activated protein kinase (AMPK), which subsequently inhibits the mechanistic target of rapamycin (mTOR) signaling pathway and alters cancer cell metabolism. Irinotecan is a cytotoxic chemotherapy agent that functions as a DNA topoisomerase 1 inhibitor, preventing DNA religation and causing double-strand breaks. The combination therapy aims to leverage the metabolic stress induced by metformin to enhance the efficacy of irinotecan in patients who have failed standard treatments.
- Other names
- metformin hydrochlorideirinotecan hydrochloride
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on metformin + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin + irinotecan.